The firm has a substantial track-record in representation of purchasers and targets in private and public merger and acquisition transactions. We regularly advise investors, companies and boards of directors on private and public mergers, including reverse mergers, mergers into publicly traded shells, asset purchases and share acquisitions.
Recent examples include:
• INX Limited in its merger with Valdy Investments Ltd. (TSXV).
• Zebra Medical Vision Ltd. in its merger with Nano-x Technologies Ltd. (Nasdaq: NNOX).
• Biosight in its merger with Advaxis Inc. (Nasdaq: ADXS).
• Cellect Biotherapeutics Ltd. (Nasdaq: APOP) in its merger with Quoin Pharmaceuticals, Inc.;
• The sale of majority equity interest of Pixcell Medical Technologies Ltd. to Soulbrain Holdings Co., Ltd.
• Famewave Ltd. and its shareholders in its acquisition by Kitov Pharma Ltd. (TASE: KTOV).
• Co-Pilot Ltd. in the transfer of its application development services business to a wholly owned subsidiary, Zemingo Technologies Ltd., and the sale of the control of such subsidiary to Emet Computing Ltd.
• Anima Biotech Ltd. in a research and collaboration agreement with Eli Lilly with a total deal value exceeding $1 billion, for the discovery and development of translation inhibitors for several target proteins by using Anima’s Translation Control Therapeutics platform.
• Eloxx Pharmaceuticals Ltd. in merger with Sevion Therapeutics, Inc.
• iOptima Ltd. and its shareholders in the sale of the company to a Chinese life sciences corporation in a transaction with an aggregate deal value of up to approximately $50 million. The complex transaction includes an initial investment of $7 million and a multi-stage acquisition of the company from its shareholders.